A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms

耐受性 医学 内科学 肿瘤科 临床研究阶段 不利影响 药理学 临床试验
作者
Nicholas J. Short,Tae Kon Kim,Rustin R. Lovewell,Elizabeth A. Griffiths,Hetty E. Carraway,Stephanie Zeidan,Elizabeth Knowles,Megan Sapp Nelson,Jahangheer Shaik,Chelsea Zhou,Emilia Alina Barbu,Zachary Cusumano,Subrata Kundu,Sasan Sharee,Ron Copeland,Dallas B. Flies,Solomon Langermann,Mei Han,Jessica K. Altman,Farhad Ravandi
出处
期刊:Blood [American Society of Hematology]
卷期号:140 (Supplement 1): 9078-9079
标识
DOI:10.1182/blood-2022-167349
摘要

Background With the exception of certain select subtypes, Acute Myeloid Leukemia (AML) remains incurable for a majority of patients with current therapies. Despite recent drug approvals targeting actionable molecular mutations and BCL-2, relapse remains inevitable for most patients with AML due to leukemia-initiating cells and progenitors {i.e., leukemic stem cells (LSCs)} which are resistant to conventional cytotoxic drugs. Novel agents that preferentially target LSCs to lessen or eliminate the risk for relapse while avoiding significant myelosuppression by sparing normal hematopoietic stem cells (HSCs), are highly sought-after anti-leukemia therapeutics. Leukocyte Associated Immunoglobulin-like Receptor 1 (LAIR-1) is an immune inhibitory receptor that is present on most immune cell subsets, including T cells, NK cells, monocytes, macrophages, dendritic cells, and granulocytes. LAIR-1, a surface leukocyte receptor containing two immune receptor tyrosine-based inhibitory motifs (ITIM), binds to endogenous collagen ligands and plays an important role in inducing an immunosuppressive microenvironment. In AML, the engagement of LAIR-1 inhibits intracellular downstream survival signals, leading to decreased GM-CSF-mediated survival and proliferation of AML blasts. LAIR-1 is expressed on AML blasts and LSCs regardless of FAB subtypes, cytogenetics or molecular mutations. Recent work demonstrates that myeloid leukemia cell lines, primary AML blasts, monoblasts and monocytes, and MDS-EB-2 blasts all express LAIR-1. Critically, while high expression of LAIR-1 is characteristic of LSCs, this receptor is minimally detectable on normal HSCs, making it an ideal anti-leukemic target. NC525 is a humanized immunoglobulin gamma 1, kappa (IgG1κ) monoclonal antibody that targets LAIR-1-expressing AML blasts and LSCs. Extensive IND-enabling preclinical studies have shown the following features of NC525: (i) Inhibition of colony formation of AML CD34+ bone marrow cells; (ii) sparing of colony formation and differentiation ability of healthy CD34+ HSCs; (iii) direct ex vivo killing of AML blasts without killing healthy leukocytes; (iv) suppression of AML in both MV4-11 and THP-1 CDX models; (v) restriction of MV4-11 in a humanized murine model, without depletion or suppression of human T cells; (vi) restriction of MV4-11 tumor growth in murine blood, spleen, and bone marrow; and (vii) reduction of AML disease burden in primary patient-derived AML xenograft (PDX) models. Finally, NC525 completely inhibits leukemia propagation in secondary transplant models, suggesting that NC525 is capable of eradicating LSCs. Furthermore, NC525 destroys leukemic cells by ligation-mediated apoptosis of leukemic blasts and stem cells without evidence of an immunomodulatory effect on other immune subsets. Methods This is an open-label, non-randomized, Phase 1 dose escalation study to determine the safety and tolerability of NC525 in adult patients with advanced myeloid neoplasms. This study will also assess the clinical benefit of NC525. Eligible patients must have relapsed or refractory AML, myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) that has progressed after standard therapy. Participants will receive NC525 by intravenous infusion on Days 1 and 15 of each 28-day cycle. During Phase 1, the safety and tolerability of NC525 will be evaluated by exploring escalating dose levels of NC525. In addition, the pharmacologically active dose (PAD), defined as the dose that provides a maximal biologic effect, such as achieving a complete remission (CR), CR with partial hematological recovery (CRh) or CR with incomplete hematological recovery (CRi), and the maximum tolerated dose (MTD) of NC525 will be determined. Safety and tolerability will be further assessed through the expansion of a few dose levels to determine an optimal recommended Phase 2 Dose (RP2D) and administration schedule of NC525, based on the PK/PD profiles. Taken together, preclinical data suggest that targeting LAIR-1 in AML and other myeloid malignancies may be an effective therapy for these diseases with the advantage of specifically eradicating leukemic stem cells and sparing normal HSCs.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
AJIN完成签到,获得积分20
刚刚
Hello应助weixin112233采纳,获得10
1秒前
1秒前
1秒前
tracer完成签到,获得积分10
3秒前
3秒前
橘子sungua完成签到,获得积分10
4秒前
4秒前
4秒前
落落完成签到,获得积分10
4秒前
橘猫完成签到,获得积分20
4秒前
阿潇发布了新的文献求助10
5秒前
5秒前
5秒前
6秒前
HF完成签到,获得积分10
6秒前
xiaokezhang发布了新的文献求助10
6秒前
Yamin发布了新的文献求助10
7秒前
akmdh完成签到,获得积分10
7秒前
独特大米完成签到,获得积分20
7秒前
壮观以松完成签到,获得积分10
7秒前
哎呀哎呀25完成签到,获得积分10
7秒前
liang发布了新的文献求助30
8秒前
peng发布了新的文献求助10
8秒前
水果完成签到,获得积分10
8秒前
科研通AI2S应助风中的夕阳采纳,获得10
8秒前
8秒前
9秒前
烊烊发布了新的文献求助10
9秒前
冷酷代珊完成签到,获得积分10
9秒前
9秒前
ylf发布了新的文献求助10
9秒前
光芒万丈完成签到,获得积分10
10秒前
10秒前
阜睿发布了新的文献求助30
10秒前
Ljh完成签到,获得积分10
10秒前
11秒前
独爱小新发布了新的文献求助10
11秒前
小羊完成签到,获得积分10
12秒前
LP发布了新的文献求助10
12秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 1000
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3245290
求助须知:如何正确求助?哪些是违规求助? 2888921
关于积分的说明 8256346
捐赠科研通 2557298
什么是DOI,文献DOI怎么找? 1385998
科研通“疑难数据库(出版商)”最低求助积分说明 650265
邀请新用户注册赠送积分活动 626527